Toya Nath Baral

TL;DR: This work designed a strategy to clone the Nb repertoire of an immunized dromedary and to select the Nbs with specificity for the authors' target antigens, which are well produced in bacteria, are very stable and highly soluble, and bind their cognate antigen with high affinity and specificity.

TL;DR: Treatment with an engineered truncated apoL-I with a single-domain antibody that efficiently targets conserved cryptic epitopes of the variant surface glycoprotein (VSG) of trypanosomes to generate a new manmade type of immunotoxin with potential fortrypanosomiasis therapy resulted in clear curative and alleviating effects on acute and chronic infections of mice with both NHS-resistant and NHS-sensitive trypanOSomes.

TL;DR: The moderate size (approximately 80 kDa) and intact human Fc make HCAbs a unique antibody format which may outperform whole IgGs as imaging and therapeutic reagents.

TL;DR: In this paper, transient expression, purification and characterization of six chimeric heavy chain antibodies (cHCAbs) or fusion of camelid single domain antibodies (sdAbs) to human fragment crystallizable (Fc) are presented.

TL;DR: This is a noninjection based approach in 1-dodecanethiol (DDT) with excellent synthetic reproducibility and large-scale capability and the bioimaging data illustrate that the CuInS2 NCs from the authors' SDPP-based low-temperature nonin injection approach are good quality.